PPLPHARMA - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:03 am

IntraDay Trade Rating: 3.3

📊 Analysis: PPLPHARMA is trading at ₹171, below both 50 DMA (₹186) and 200 DMA (₹198), reflecting short-term weakness. RSI at 22.7 indicates oversold conditions, while MACD (-6.50) confirms bearish momentum. Intraday volume (28,15,670) is slightly below the 1-week average (30,04,571), suggesting moderate participation. Fundamentals are average with ROCE (12.4%) and ROE (9.74%), but valuations are slightly expensive (P/E 32.2 vs industry PE 30.6). Intraday trades should be defensive.

💡 Optimal Buy Price: ₹168–₹172 (near support zone).

🎯 Profit-Taking Levels: ₹178 – ₹184 (short-term resistance).

🛡️ Stop-Loss: ₹165 (below intraday support).

⏱️ Exit Strategy if Already Holding: Exit intraday if price fails to sustain above ₹171 with weakening momentum. If RSI remains below 25 and MACD stays negative, consider closing positions near ₹168–₹171. If momentum improves with volume pickup, hold until ₹178–₹184.

Positive

• 📈 Quarterly PAT improved from ₹113 Cr. to ₹196 Cr.
• 💡 DII holding increased (+0.64%), showing domestic investor confidence.
• ⚡ Debt-to-equity 0.12 indicates low leverage risk.
• 📊 PEG Ratio 1.45 suggests fair valuation relative to growth.

Limitation

• 📉 Current price below DMA 50 & DMA 200, reflecting bearish trend.
• 📊 RSI 22.7 shows oversold but weak momentum.
• 📉 Dividend Yield 0.08% is negligible.

Company Negative News

• ⚠️ FII holding reduced (-0.59%), showing foreign investor caution.
• 📉 Quarterly PAT variation (-6.54%) indicates earnings pressure despite sequential improvement.

Company Positive News

• ✅ Sequential PAT growth from ₹113 Cr. to ₹196 Cr. shows operational improvement.
• 💡 DII holding increased, supporting domestic sentiment.

Industry

• 🏭 Industry PE at 30.6 vs stock PE 32.2, showing slight premium valuation.
• 📊 Pharma sector remains resilient with long-term demand drivers.

Conclusion

⚖️ PPLPHARMA shows oversold technicals with weak short-term momentum but improving fundamentals. Intraday traders should be cautious, buying near support (₹168–₹172) with tight stop-losses. Upside is possible toward ₹178–₹184 if momentum improves. Long-term investors may remain cautious due to modest efficiency and premium valuation, but intraday trades can be attempted defensively today.

Would you like me to extend this into a peer benchmarking overlay comparing PPLPHARMA with other pharma mid-cap stocks, or prepare a sector rotation basket scan to highlight stronger intraday momentum candidates?